🔗 Share this article

Following a postponement and a remarkably divisive meeting, a federal vaccine advisory panel was set to cast ballots on Friday concerning altering the longstanding recommendation that every infant be inoculated against hepatitis B.

Fiery Exchange and a Postponed Decision

The opening session of the conference on Thursday was marked by heated debate over restricting access to the hepatitis B vaccine for babies and a decision to delay the ballot by a day to allow panelists additional time to review the wording. The committee, which counsels the Centers for Disease Control and Prevention on immunization practices, had put off the vote twice in the past.

“Is there any concrete proof of injury of giving this immunization before 30 days? Or is this theory?” questioned one panel member.

In reply, another participant stated, “There is limited evidence about the enduring danger.”

Present Protocol and Likely Ramifications

The vaccine is currently recommended for each baby within 24 hours of being born to prevent infection of hepatitis B, which can lead to significant hepatic injury. It has been administered to 1.4 billion people for in excess of thirty years.

The meeting in Atlanta presented no recent proof of harms caused by the vaccine. Experts say any alteration to the present hepatitis B immunization timeline could have profound and widespread implications for infant and child health in the United States.

Group Membership and New Appointments

The consultative group can only offer guidance to the director of the CDC. The panel's membership has undergone changes this week, with the announcement that the panel's latest chairman would leave for an formal position and be substituted with a heart specialist who has been skeptical about other inoculations.

The board includes several vaccine skeptics who support a goal to reform – and potentially, in some cases, scrap – longstanding vaccine advisories.